Frequently asked questions

TWYCE coordinates two complementary signals: tumor-directed activation (Signal 1) and TME-anchored CD28 costimulation (Signal 2). Our approach is designed to provide costimulation within the usually immunosuppressive TME to achieve more potent and sustained T cell responses in solid tumors.

BiCo stands for bispecific costimulator. A BiCo binds a selected target in the TME and then stimulates CD28 on T cells, delivering the costimulatory Signal 2 where it is required to support sustained T cell activity. Its patented format combines bivalent CD28 binding with strict target restriction.

BiCo-3 is the TWYCE lead candidate (FAP × CD28). It targets FAP in the TME and is designed to boost Signal 1 provided by TCEs or cancer vaccines by target-restricted CD28 costimulation.

The pipeline combines the clinical Signal 1 programs CC-1 (PSMA×CD3) and CC-3 (CD276×CD3) with BiCo-3 (FAP×CD28), the Signal 2 lead candidate. BiCo-3 will initially be evaluated as a monotherapy before progressing into combinations with the CD3-based TCEs and cancer vaccines. Smart TriCo, a preclinical trispecific format, integrates both signals in one molecule.

Yes. The TWYCE bispecific costimulator, your Signal 1 provider, or ours. TWYCE can pair its CD28-based Signal 2 platform with internal Signal 1 candidates and vaccines, as well as partner-provided CD3 engagers and cancer vaccines or other selected Signal 1 approaches, and is open to licensing, co-development and broader platform alliances.